RG 004
Alternative Names: RG-004Latest Information Update: 31 Mar 2025
At a glance
- Originator RinuaGene Biotechnology
- Class Respiratory syncytial virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 28 Feb 2025 Preclinical trials in Respiratory syncytial virus infections (Prevention) in China (Parenteral), prior to February 2025 (RinuaGene Biotechnology pipeline, February 2025)
- 29 Feb 2024 RinuaGene Biotechnology has patents pending for "Engineered dna molecule for coding rna" worldwide
- 17 Jan 2024 RinuaGene Biotechnology has patents pending for "Lipid compounds and lipid nanoparticles compositions" in Taiwan